Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on 4D Molecular Therapeutics (NASDAQ:FDMT) in the last three months. Summarizing their recent ...
In the assessment of 12-month price targets, analysts unveil insights for 4D Molecular Therapeutics, presenting an average target of $30.33, a high estimate of $46.00, and a low estimate of $6.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results